Evidence map›Paper›PMID 39735668›Full record

ArticleOncology research2025

Genetic signatures of

Enrico Caliman, Sara Fancelli, Federico Scolari, Adriano Pasqui, Clara Manneschi, Daniele Lavacchi, Francesca Mazzoni, Francesca Gensini, Valeria Pasini, Camilla Eva Comin and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Enrico CalimanClinical Oncology Unit, Careggi University Hospital, Florence, 50134, Italy.
Sara FancelliClinical Oncology Unit, Careggi University Hospital, Florence, 50134, Italy.
Federico ScolariDepartment of Health Sciences, University of Florence, Florence, 50134, Italy.
Adriano PasquiMedical Oncology Unit, Careggi University Hospital, Florence, 50134, Italy.
Clara ManneschiMedical Oncology Unit, Careggi University Hospital, Florence, 50134, Italy.
Daniele LavacchiClinical Oncology Unit, Careggi University Hospital, Florence, 50134, Italy.
Francesca MazzoniMedical Oncology Unit, Careggi University Hospital, Florence, 50134, Italy.
Francesca GensiniDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, 50134, Italy.
Valeria PasiniSection of Anatomic Pathology, Department of Health Sciences, University of Florence, Florence, 50139, Italy.
Camilla Eva CominDepartment of Experimental and Clinical Medicine, University of Florence, Florence, 50134, Italy.
Luca VoltoliniDepartment of Experimental and Clinical Medicine, University of Florence, Florence, 50134, Italy.
Serena PillozziClinical Oncology Unit, Careggi University Hospital, Florence, 50134, Italy.
Lorenzo AntonuzzoClinical Oncology Unit, Careggi University Hospital, Florence, 50134, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Platinum chemotherapy (CT) remains the backbone of systemic therapy for patients with small-cell lung cancer (SCLC). The nucleotide excision repair (NER) pathway plays a central role in the repair of the DNA damage exerted by platinum agents. Alteration in this repair mechanism may affect patients' survival. Materials and Methods: We conducted a retrospective analysis of data from 38 patients with extensive disease (ED)-SCLC who underwent platinum-CT at the Clinical Oncology Unit, Careggi University Hospital, Florence (Italy), from 2015 to 2020. mRNA expression analysis and single nucleotide polymorphism (SNP) characterization of three NER pathway genes-namely Results: Overall, elevated expression of Conclusions: The comprehensive analysis of

Indexed as

DNA-Binding ProteinsEndonucleasesLung NeoplasmsPolymorphism, Single NucleotideSmall Cell Lung CarcinomaXeroderma Pigmentosum Group D ProteinAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorDNA Excision Repair Protein ERCC-5DNA RepairFemaleHumansMaleBiomarkers, TumorDNA-Binding ProteinsDNA Excision Repair Protein ERCC-5EndonucleasesERCC1 protein, humanERCC2 protein, humanNuclear ProteinsPlatinumTranscription FactorsXeroderma Pigmentosum Group D ProteinERCC genesNucleotide excision repair (NER) pathwayPlatinum-chemotherapy (CT)Single nucleotide polymorphisms (SNPs)Small cell lung cancer (SCLC)

Identifiers

PMID39735668
PMCPMC11671403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.